Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person:  The amounts reported in boxes 6, 8, and 9 represent 282,996 shares of common stock, par value $0.0001 per share ("Common Stock"), of Yarrow Bioscience, Inc. (the "Issuer") owned directly by private investment funds managed by ADAR1 Capital Management, LLC. Such securities may be deemed to be indirectly beneficially owned by ADAR1 Capital Management, LLC. The percentage in box 11 is based on 11,473,285 shares of Common Stock outstanding as of September 30, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2026, filed with the Securities and Exchange Commission on November 13, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person:  The amounts reported in boxes 6, 8, and 9 represent 282,996 shares of common stock, par value $0.0001 per share ("Common Stock"), of Yarrow Bioscience, Inc. (the "Issuer") owned directly by private investment funds managed by ADAR1 Capital Management, LLC. Such securities may be deemed to be indirectly beneficially owned by Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC. The percentage in box 11 is based on 11,473,285 shares of Common Stock outstanding as of September 30, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2026, filed with the Securities and Exchange Commission on November 13, 2026


SCHEDULE 13G



 
ADAR1 Capital Management, LLC
 
Signature:/s/ Daniel Schneeberger
Name/Title:Daniel Schneeberger, Manager
Date:11/16/2026
 
Daniel Schneeberger
 
Signature:/s/ Daniel Schneeberger
Name/Title:Daniel Schneeberger, in his individual capacity
Date:11/16/2026